Alignment Healthcare, Inc. (ALHC) Stock Price & How to Invest

Alignment Healthcare operates Medicare Advantage health plans, mostly in California and a handful of other states, serving roughly 285,000 members as of early 2026. Its model pairs a customized clinical care approach with a purpose-built technology platform (branded AVA) and local provider partnerships, aiming to deliver better health outcomes at lower cost than legacy insurers. High Star Ratings (generally in the 4 to 5 range) are central to the thesis because they drive bonus payments and help attract members.

The investment picture is one of a growth company reaching an earnings inflection. Revenue grew about 33% year over year in Q1 2026 to ~$1.24 billion, and the company posted its first quarterly net income (~$11 million) after years of losses, while raising full-year guidance. The trade-off is valuation: with a trailing P/E in the hundreds, the stock discounts continued rapid membership growth and steady medical-cost discipline, leaving little room for execution stumbles or a cost-ratio reversal.

Medical costs are the dominant swing factor: a reversion in utilization, an unexpected cost shock, or unfavorable risk-adjustment changes could quickly compress the thin margins. Membership is geographically concentrated (heavy California exposure), so state-level competition or regulatory shifts carry outsized impact. CMS policy on Star Ratings, rate benchmarks, and risk coding directly affects revenue and bonus payments. The valuation is demanding, with a trailing P/E in the hundreds, so any growth deceleration or margin miss could drive a sharp de-rating. It also competes against far larger, better-capitalized insurers that can pressure pricing and benefits.

13 analysts publish price targets on ALHC, averaging $24.62 against a $14.85 price as of August 2026, or +65.8%. The published targets run from $16.00 to $30.00, a moderate spread, and the ratings split 12 buy, 2 hold, 0 sell. Over the last six months there have been 2 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ALHC forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Alignment Healthcare, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Membership growth engine. ALHC has compounded health plan membership at roughly 30% per year since its 2021 IPO, reaching ~285,000 members in Q1 2026. The most optimistic published target, $30.00, assumes this works close to its best case.

The case against. Medical costs are the dominant swing factor: a reversion in utilization, an unexpected cost shock, or unfavorable risk-adjustment changes could quickly compress the thin margins. The most pessimistic target, $16.00, is roughly what ALHC is worth if this bites instead.

Read the full bull and bear case on ALHC, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Alignment Healthcare, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$4.5B
• Q1 2026 revenue (YoY): ~$1.24B (+33%)
• 2026 revenue guidance: ~$5.14B to $5.19B
• Adjusted EBITDA (2026 guide): ~$133M to $163M
• Health plan members: ~285,000
• Market cap: ~$5B

ALHC recently crossed into profitability, posting ~$11 million of net income in Q1 2026 versus a prior-year loss, which leaves the trailing P/E extremely high (well over 100x) and makes the stock look expensive on current earnings. The bull case rests on forward growth and margin expansion rather than trailing profits. Shares traded around the low-to-mid $20s in mid-2026, near 52-week highs.

Other names that sit close to ALHC: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ALHC exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ALHC sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ALHC fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

ALHC is a scaling, star-rated Medicare Advantage operator hitting a profitability inflection, priced for continued growth and disciplined medical costs.

Whether ALHC is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ALHC a buy or a sell?, and where the stock could go from here in the ALHC stock forecast.

For income investors, whether ALHC pays a dividend and how the payout looks is covered in does ALHC pay a dividend? And to weigh ALHC against a peer, read the full side-by-side comparisons: ALHC vs UNH and ALHC vs HUM.